An interventional study of Bubble Positive Expiratory Pressure (Bubble-PEP) Therapy in Cardiac Surgery and Open Heart Surgery, sponsored by Afyonkarahisar Health Sciences University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Afyonkarahisar Health Sciences University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Dyspnea with a site in Turkey — 17 open to participants now, 20 under way, none of them phase 3. Dyspnea · Turkey.
Among the 84 studies in Dyspnea with a site in Turkey, this one is the 13th largest by planned enrollment of the 60 interventional ones that give a count, is one of 9 that started in 2026, is one of 58 with no phase, reaches primary completion later than 17 of the 19 other live ones, and was the 84th registered.
893 studies on the registry are indexed under Dyspnea; 188 are open to participants now.
Browse Dyspnea studies →17 of the 84 studies in Dyspnea with a site in Turkey are open now. Recruiting first, the newest first:
Mersin University · Sites in Turkey
Ages 18+
Alper Kemal Gürbüz · Sites in Turkey
Ages 18+ · Healthy volunteers
University of Gaziantep · Sites in Turkey
Ages 18–65
Emine ŞAHİN · Sites in Turkey
Ages 1–17
Izmir Democracy University · Sites in Turkey
Ages 6–18
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 126 Dyspnea studies recruiting now, 69 (55%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 9 started in 2026.
This study's planned enrollment of 92 is above the median of 50 across 586 interventional studies indexed under Dyspnea.
Median enrollment 60 across the 60 interventional studies, 77 across the 24 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 84 have an industry lead sponsor. The 10 most frequent:
Afyonkarahisar Health Sciences University is the lead sponsor of 117 studies on the registry; 33 are open to participants now.
Afyonkarahisar Health Sciences University has 1 study filed under Dyspnea — fewer than ten, so there is no comparison to draw.
6 of the studies in Dyspnea with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07752706Istanbul University - CerrahpasaBreathing Exercises for Dyspnea and Anxiety in Heart Failure | 2026-12-05 |
| NCT07183956Muğla Sıtkı Koçman UniversityComparison of the Silverman-Andersen Score and the Downes Score | 2026-12-15 |
| NCT06984679Izmir Democracy UniversityPhysical Impairments in Children With Cystic Fibrosis | 2027-03-01 |
| NCT07945483Afyonkarahisar Health Sciences UniversityEffects of Bubble-PEP After Open Heart Surgery on Blood Gases, Dyspnea, Secretion Status, and Pain | 2027-04-01 |
| NCT07805603Medipol UniversityHERMES: Quality and Safety of Advanced Respiratory Support During Patient Transport | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 84 studies in Dyspnea with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled study aims to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain in patients undergoing open-heart surgery.
The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. A total of 92 adult patients undergoing coronary artery bypass grafting or heart valve surgery will be included. Participants will be randomly assigned to an intervention group (n=46) or a control group (n=46) using stratified block randomization based on surgical procedure.
Both groups will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry. In addition to standard care, the intervention group will receive Bubble-PEP therapy twice daily for three consecutive days following extubation. Each session will consist of three sets of 10 expirations.
Arterial blood gas parameters, dyspnea, respiratory secretion status, and pain will be assessed at baseline, during follow-up, and after completion of the intervention. Patient satisfaction will also be evaluated.
The study aims to determine whether adding Bubble-PEP therapy to standard postoperative care improves respiratory outcomes and contributes to evidence-based nursing care following open-heart surgery.
Study Design and Setting This study is designed as a randomized controlled trial to investigate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain following open-heart surgery.
The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. Ethical approval was obtained from the Non-Interventional Scientific Research Ethics Committee of Afyonkarahisar Health Sciences University on October 2, 2026 (Decision No. 740).
Participants and Sample Size The study will include 92 adult patients undergoing coronary artery bypass grafting (CABG) or heart valve surgery, with 46 patients assigned to each group.
The sample size was calculated using G*Power 3.1.9.7, based on an effect size of 0.659 for PaO2, a significance level of 0.05, and 80% statistical power. The initial sample size was 76 participants, which was increased to 92 to account for an anticipated 20% dropout rate.
Eligible participants will be aged 18 years or older, have undergone CABG or heart valve surgery, be extubated and hemodynamically stable, be able to communicate in Turkish, and provide informed consent.
Randomization and Blinding Participants will be allocated to intervention and control groups in a 1:1 ratio using stratified block randomization according to surgical type (CABG or heart valve surgery).
Computer-generated randomization lists will be prepared by an independent researcher who is not involved in intervention delivery or outcome assessment. Group allocation will be implemented using sequentially numbered, sealed envelopes.
Due to the nature of the intervention, participants and the researcher administering Bubble-PEP therapy cannot be blinded. However, outcome assessments will be conducted by an independent assessor blinded to group allocation. The statistician will also remain blinded to group identity until completion of the analysis.
Control Group Participants in the control group will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry.
Intervention Group Participants in the intervention group will receive Bubble-PEP therapy in addition to standard postoperative care.
The Bubble-PEP apparatus will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and a tube approximately 80 cm long with an internal diameter of 8 mm. A separate bottle and tube will be provided for each participant.
Bubble-PEP therapy will begin after extubation, once the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician.
During the intervention, patients will be placed in an upright sitting position and instructed to inhale deeply through the nose and then exhale slowly, continuously, and in a controlled manner through the tube submerged in water.
The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.
Outcome Measurements
The primary outcome measures will include:
Arterial blood gas parameters: PaO2, PaCO2, pH, HCO3-, base excess (BE), and oxygen saturation (SpO2).
Dyspnea severity assessed using the Modified Borg Dyspnea Scale. Respiratory secretion status and cough effectiveness assessed using a researcher-developed postoperative respiratory secretion and cough effectiveness assessment form.
Secondary outcome measures will include:
Pain intensity assessed using the Visual Analog Scale (VAS). Patient satisfaction assessed using a visual patient satisfaction scale.
Data Collection and Assessment Schedule Preoperative demographic and clinical data will be collected after obtaining written informed consent. Preoperative dyspnea and pain assessments will also be performed.
The first calendar day following extubation will be designated as Day 1 (G1). Baseline postoperative assessments will be performed on Day 1, before the first Bubble-PEP session, preferably between 09:00 and 10:00, provided that at least six hours have elapsed since extubation and the patient is hemodynamically stable.
Follow-up assessments will be performed on Days 2 and 3 (G2 and G3), between 09:00 and 10:00, before the daily intervention.
The final assessment will be performed on Day 4 (G4), between 09:00 and 10:00, following completion of the three-day intervention period. Patient satisfaction will also be evaluated during the final assessment.
Arterial blood gas results obtained as part of routine clinical care will be recorded from patient records.
Statistical Analysis Data will be analyzed using SPSS software. Descriptive statistics will include frequencies, percentages, means, and standard deviations.
Depending on the distribution of the data, independent-samples t-tests or Mann-Whitney U tests will be used for between-group comparisons. Paired t-tests or Wilcoxon signed-rank tests will be used for within-group comparisons.
Repeated-measures analysis of variance or Friedman tests will be used to evaluate changes over time, as appropriate. Exploratory subgroup analyses based on surgical type may be performed if the sample size is sufficient.
Statistical significance will be set at p \< 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients in the intervention group will receive Bubble Positive Expiratory Pressure (Bubble-PEP) therapy in addition to routine postoperative care following open-heart surgery. I will evaluate the intervention's effects on arterial blood gas parameters, dyspnea, secretion status, and pain.
Device: Bubble Positive Expiratory Pressure (Bubble-PEP) Therapy
Patients in the control group will receive routine postoperative care following open-heart surgery, with no additional interventions applied. I will assess arterial blood gas parameters, dyspnea, secretion status, and pain.
A researcher-prepared Bubble Positive Expiratory Pressure (Bubble-PEP) device will be used in addition to standard postoperative care. The device will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and an approximately 80-cm-long tube with an internal diameter of 8 mm. Each patient will be provided with an individual bottle and tube. Bubble-PEP therapy will be initiated after extubation when the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician. During the intervention, the patient will be placed in an upright sitting position and instructed to inhale deeply through the nose, followed by slow, controlled, and continuous exhalation through the tube submerged in water. The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.
Also known as: Bottle Positive Expiratory Pressure (Bottle-PEP)
Change in Arterial Oxygen Partial Pressure(PaO₂)
Arterial oxygen partial pressure(PaO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.
Time frame: Days 1, 2, and 3 post-extubation
Change in Arterial Carbon Dioxide Partial Pressure(PaCO₂)
Arterial carbon dioxide partial pressure (PaCO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaCO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.
Time frame: Days 1, 2, and 3 post-extubation
Change in Arterial Blood pH
Arterial blood pH will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in arterial blood pH will be evaluated and compared between the Bubble-PEP intervention group and the control group.
Time frame: Days 1, 2, and 3 post-extubation
Change in Arterial Oxygen Saturation (SaO₂)
Arterial oxygen saturation (SaO₂, %) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in SaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.
Time frame: Days 1, 2, and 3 post-extubation
Change in Arterial Bicarbonate Level (HCO₃-)
Arterial bicarbonate levels (HCO₃-, mmol/L) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in HCO₃- levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.
Time frame: Days 1, 2, and 3 post-extubation
Change in Arterial Blood Base Excess (BE)
Arterial blood base excess (BE, mmol/L) will be assessed using arterial blood samples obtained from patients following open-heart surgery. Changes in BE levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.
Time frame: Days 1, 2, and 3 post-extubation
Change in Dyspnea Severity
Dyspnea severity will be assessed in patients following open heart surgery using a standardized dyspnea assessment scale. Changes in dyspnea scores will be evaluated and compared between the Bubble-PEP intervention group and the control group. Higher scores will indicate greater dyspnea severity.
Time frame: Days 1, 2, and 3 post-extubation
Change in Respiratory Secretion Status
Respiratory secretion status will be assessed in patients following open heart surgery to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on airway secretion clearance. Changes in secretion status will be evaluated and compared between the intervention and control groups.
Time frame: Days 1, 2, and 3 post-extubation
Change in Postoperative Pain Intensity
Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in pain scores will be compared between the Bubble-PEP intervention group and the control group.
Time frame: Days 1, 2, and 3 post-extubation
Plan to share: No — Individual participant data will not be made publicly available or shared with other researchers. The study involves patients undergoing open-heart surgery, and participant confidentiality and data privacy will be maintained in accordance with the approved research protocol and applicable ethical and data protection requirements.
Start is estimated for Nov 2026; primary completion for Apr 2027, 4 months later.
Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Afyonkarahisar Health Sciences University →